TABLE 5

Euglycemic clamp data in the three study groups

NAFLD patientsType 2 diabetic patientsControl subjects
n301010
Steady-state glucose (mmol/l)5.0 ± 0.3 (4.4–5.6)5.1 ± 0.2 (4.9–5.5)4.9 ± 0.2 (4.6–5.2)
Steady-state insulin (pmol/l)667 ± 103 (487–940)722 ± 122 (581–918)*590 ± 55 (531–696)
Glucose infusion rate (μmol · kg−1 · min−1)19.5 ± 5.7 (10.4–33.6)*16.2 ± 4.0 (10.8–23.2)*37.2 ± 9.4 (24.7–58.4)
Glucose disposal rate (μmol · kg−1 · min−1)18.4 ± 5.9 (8.2–31.6)*18.0 ± 4.0 (13.2–26.1)*36.8 ± 7.6 (26.2–54.7)
Fasting FFAs (mmol/l)0.67 ± 0.27 (0.26–1.30)*0.55 ± 0.11 (0.44–0.81)*0.37 ± 0.12 (0.23–0.61)
End-of-clamp FFAs (mmol/l)0.21 ± 0.14 (0.05–0.55)*0.13 ± 0.05 (0.06–0.20)*0.06 ± 0.02 (0.03–0.10)
  • Data are means ± SD (range).

  • *

    * P < 0.001 vs. control subjects.